Drug
Lenalidomide 10 mg
Lenalidomide 10 mg is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_2
2
50%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 31 (25.0%)
N/A1 (25.0%)
Trials by Status
not_yet_recruiting125%
completed250%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingnot_applicable
Lenalidomide in the Treatment of Mucosal Behçet's Syndrome
NCT05449548
completedphase_2
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
NCT04032626
not_yet_recruitingphase_2
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment
NCT06177028
completedphase_3
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
NCT00179621
Clinical Trials (4)
Showing 4 of 4 trials
NCT05449548Not Applicable
Lenalidomide in the Treatment of Mucosal Behçet's Syndrome
NCT04032626Phase 2
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
NCT06177028Phase 2
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment
NCT00179621Phase 3
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4